Evidence map›Paper›PMID 27062704›Full record

ArticleCancer biomarkers : section A of Disease markers2016

Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.

Xiao-Feng Xu, Ren-Quan Lu, Ran Xiao, Lei Zhou, Xin-Min Zhao, Xi-Chun Hu, Xiang Gao, Lin Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiao-Feng XuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Ren-Quan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Ran XiaoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lei ZhouDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Xin-Min ZhaoDepartment of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Xi-Chun HuDepartment of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Xiang GaoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNasopharyngeal carcinoma (NPC) is a common type of head and neck cancer.

objectiveThis study aimed to detect the expression of Epstein-Barr viral Rta protein in patients with untreated NPC, and compare the serum Rta-IgG with the VCA-IgA in patients with NPC.

methodsIn the current work, the nasopharyngeal tissues of untreated NPC patients (n= 13) and non-NPC controls (n= 10) were collected for the immunohistochemical (IHC) staining to analyze the levels of Rta protein expression, meanwhile serum samples from the participants were prepared to assess the roles of Rta-IgG level with Enzyme-linked immunosorbence assay (ELISA) in diagnosis of NPC including the patients with NPC, the patients with other cancers, and normal volunteers.

resultsThe levels of serum Rta-IgG in 26 NPC patients were monitored at pre- and post-treatments, as well as one to two year after. We found that there was a significant difference of the expression levels of Rta protein between NPC and non-NPC groups (P< 0.05). Correspondingly, the levels of serum Rta-IgG in NPC patients (3.05, 1.19-4.95) were significantly higher than those of non-NPC participants (0.15, 0.08-0.30, P< 0.05) including the patients with lung cancer (0.14, 0.08-0.19), the patients with breast carcinoma (0.17, 0.10-0.25), the patients with gastric carcinoma (0.08, 0.05-0.16), the patients with malignant lymphoma (0.13, 0.08-0.20), the patients with benign nasopharyngeal disease (1.65, 0.74-1.93) and healthy volunteers (0.22, 0.13-0.32), respectively. With a receiver operation characteristic (ROC) analysis, the cut-off value to discriminate NPC patients from the controls was established at 0.92 (S/CO) for Rta-IgG (sensitivity 83.6%; specificity 82.4%), the diagnosis efficacy of Rta-IgG was higher than VCA-IgA. The positive rates of Rta-IgG were related to clinical stage, but not metastatic sites. Serum concentrations of Rta-IgG were decreased in NPC patients with effective radiation, and slightly raised or with no change with ineffective radiation.

conclusionsRta expression levels are elevated in the patients with NPC, and serum Rta-IgG is a promising biomarker in both differential diagnosis and therapy-monitoring of the patients with NPC.

Indexed as

AdultAgedAntibodies, ViralAntigens, ViralBiomarkers, TumorBreast NeoplasmsCapsid ProteinsCarcinomaEnzyme-Linked Immunosorbent AssayFemaleHerpesvirus 4, HumanHumansImmediate-Early ProteinsImmunoglobulin GLung NeoplasmsLymphomaAntibodies, ViralAntigens, ViralBiomarkers, TumorCapsid ProteinsEpstein-Barr viral capsid antigenImmediate-Early ProteinsImmunoglobulin GRta protein, Human herpesvirus 8Trans-ActivatorsEnzyme-linked immunosorbent assay (ELISA)Epstein-Barr virusNasopharyngeal carcinomaRta proteinVCA-IgA

Identifiers

PMID27062704
PMCPMC13016500
OpenAlexW2293767517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.